- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic plaque psoriasis Psoriatic arthritis Rheumatoid arthritis Ulcerative arthritis
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 767KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 53KB)
Tofacitinib – November 2020
Tofacitinib: Tablet 5 mg, Tablet 10 mg; Xeljanz®
Last updated
30 May 2025